Gamma-Secretase Modulators for Alzheimer's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease and related conditions, such as cerebral amyloid angiopathy and inclusion body myositis, lack effective methods to prevent or reverse the clinical symptoms and underlying pathophysiology associated with β-amyloid peptide production, particularly focusing on the reduction of toxic β-amyloid 42 aggregates.
Innovation Solution
Development of compounds that selectively inhibit γ-secretase, thereby reducing the production of β-amyloid 42 by directing the γ-secretase-mediated cleavage of APP to produce shorter, less neurotoxic forms of β-amyloid, which are less likely to aggregate, and their pharmaceutical compositions for use in treating Alzheimer's Disease, Down Syndrome, and other β-amyloid-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If γ-secretase is inhibited to reduce β-amyloid 42 production, then the neurotoxicity and aggregation are reduced, but the production of all β-amyloid peptides including beneficial forms is decreased
Solution Approach 1:
The patent applies local quality by designing compounds that selectively inhibit γ-secretase at specific molecular sites to preferentially reduce β-amyloid 42 production while preserving the generation of shorter, less toxic β-amyloid forms. This selective inhibition approach targets the harmful aspect (Aβ42) without completely blocking all β-amyloid production, thereby resolving the contradiction between reducing neurotoxicity and maintaining beneficial peptide production.
Solution Approach 2:
The invention employs parameter changes by modifying the chemical structure of γ-secretase inhibitors to achieve differential inhibition kinetics. By adjusting molecular parameters such as lipophilicity, steric bulk, and electronic properties, the compounds can selectively reduce Aβ42 production while allowing continued production of shorter β-amyloid peptides, thus resolving the contradiction between harmful factor reduction and substance quantity maintenance.
2Ease of operation
If current Alzheimer's disease treatments are used, then symptomatic management is provided, but the underlying pathophysiology and clinical symptoms cannot be prevented or reversed
Solution Approach 1:
The patent applies preliminary action by using γ-secretase modulators that can prevent the formation of toxic β-amyloid 42 aggregates before they cause neuronal damage. By intervening early in the pathophysiological process rather than treating established symptoms, these compounds aim to prevent disease progression and potentially reverse early pathological changes, thereby addressing the unreliability of current symptomatic-only treatments.
Solution Approach 2:
The invention converts the harmful overproduction of β-amyloid into a beneficial outcome by using γ-secretase modulators that redirect cleavage to produce shorter, less toxic β-amyloid forms. This transforms the pathological process of β-amyloid generation into a protective mechanism, where the same enzymatic pathway is harnessed to produce beneficial peptides while avoiding toxic aggregation, thus achieving both prevention and potential reversal of disease pathology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce β-amyloid levels, potentially preventing the onset and progression of Alzheimer's Disease and other β-amyloid-dependent conditions by minimizing the production of the toxic β-amyloid 42 peptide, thereby addressing the underlying pathophysiology and clinical symptoms.
Implementation Method 1
β-amyloid (Aβ) peptides that are formed by a stepwise proteolytic cleavage of the amyloid precursor protein (APP) by β-site APP-cleaving enzyme (BACE), to generate the N-terminus, and γ-secretase, to generate the C-terminus
Implementation Method 2
Inhibitors of the enzymes that form Aβ42, such as γ-secretase, represent potential disease-modifying therapeutics for the treatment of AD
Data Source
AI summary
The present disclosure provides a series of compounds of the formula (I) which modulate ß-amyloid peptide (ß-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ß-amyloid peptide (ß-AP) production.